US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer

Posted by on December 30, 2011 in Market Research

US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer 

Description

Experience real patient situations that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced lung cancer.

Case highlights include:

  • Smoker with squamous cell carcinoma
  • Light smoker with adenocarcinoma
  • Nonsmoker with adenocarcinoma
  • Former light smoker whose cancer is EGFR positive

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance

Table of Contents

Executive Summary
Chapter 1: Introduction
Table 1: Treatment Options in Advanced Lung Cancer
Chapter 2: Respondent Demographics
Table 2: Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Lung Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of a Smoker with Squamous Cell Carcinoma
Figure 3.1 Laboratory studies to be done on the tumor tissue
Figure 3.2 First-line chemotherapy regimen
Figure 3.4 Confidence in treating this patient to an optimal outcome
Figure 3.5 Next step in management
Figure 3.6 Subsequent treatment regimen
Figure 3.7 Treatment at next cancer progression
Figure 3.8 Factors influencing treatment decisions
Chapter 4: Treatment of a Light Smoker with Adenocarcinoma
Figure 4.1 Barriers to an optimal outcome
Figure 4.2 Confidence in treating patient to an optimal outcome
Figure 4.3 Laboratory studies to order
Figure 4.4 First-line chemotherapy regimen
Figure 4.5 Next step in management
Figure 4.6 Second-line treatment regimen
Figure 4.7 Factors influencing treatment decision
Chapter 5: Treatment of a Never-smoker with Adenocarcinoma
Figure 5.1 Laboratory studies to order
Figure 5.2 Confidence in treating patient to an optimal outcome
Figure 5.3 Next step in management
Figure 5.4 Whether to wait for results of testing before beginning systemic therapy
Figure 5.5 First-line chemotherapy regimen
Figure 5.6 Factors influencing treatment decision
Chapter 6: Treatment of an EGFR Mutation Positive Adenocarcinoma
Figure 6.1 First-line chemotherapy regimen
Figure 6.2 Factors influencing treatment decision
Figure 6.3 Confidence in treating patient to an optimal outcome
Figure 6.4 Factors influencing treatment decision
Figure 6.5 Sequence of treatment choices
Figure 6.6 Barriers to management of advanced lung cancer
Chapter 7: Summary
Appendix A: Survey Instrument

Related posts:

  1. US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin’s Lymphoma
  2. US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
  3. US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma
  4. US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin’s Lymphoma
  5. Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers

Comments are closed.